Mar. 21 at 12:13 PM
$NWBO
Why a Buyout of NWBO at Actelion‑Level (~
$30B) Is Plausible!
(Actelion was the largest single‑franchise biotech buyout in history)
If DCVax‑L receives regulatory approval, NWBO becomes one of the purest single‑franchise buyout cases in biotech history.
The logic is straightforward:
- Single product (DCVax‑L)
- Single indication (GBM)
- Monopoly‑like market (no effective competitors)
- High pricing power (oncology + cell therapy + orphan)
- Platform potential (but undeveloped by NWBO → strategic upside for buyer)
- Post‑approval status eliminates risk and maximizes valuation
This combination makes a
$20–40B buyout not only imaginable but structurally justified!
Wishing you lots of fun and a wonderful weekend!